The Future of Psychedelic Therapy - CSE: HAVN | FRA: 5NP
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The Future of Psychedelic Therapy CSE: HAVN | FRA: 5NP
INVESTMENT HIGHLIGHTS
HAVN Life is focused on the rapidly growing field of psychedelic medicine. We have the opportunity to lead the
standardization of psychedelic supply to shift human performance and mental health paradigms.
DEFINED ROUTE TO NATURAL HEALTH PRODUCTS MARKET. DEVELOPING STATE-OF-THE-ART MYCOLOGY LAB FOR
PSYCHEDELIC EXTRACTION.
PRODUCT FORMULATION OF EFFECTIVE MICRODOSING OF
NOVEL PSYCHOACTIVE COMPOUNDS. PARTNERSHIP WITH CANADIAN VETERANS FOR PHASE 1
PRE-CLINICAL RESEARCH.
MANAGEMENT TEAM WITH EXTENSIVE CLINICAL & NHP
PRODUCT DEVELOPMENT EXPERIENCE. RECEIVED FIRST HEALTH CANADA LICENSE IN 2020.
D I V E RS E M A N AG E M E NT TE A M
Investor Deck 2021 2
MISSION
Our mission is to unlock
human performance using
evidence-informed research.
We are focused on standardized,
quality-controlled extraction of
psychoactive compounds from
plants and fungi, and the
development of natural health care
products from novel compounds.
Investor Deck 2021 3
CORE PILLARS
HAVN Labs HAVN Retail
A GMP laboratory that will be dedicated HAVN Life will be developing custom
to growing and developing extraction formulations that will deliver natural health
methodology of psychoactive and products with increased bioavailability to
psychedelic compounds. support better quality outcomes.
Standardized supply of psychedelics to Through in-house product formulation and
support innovative therapies. brand acquisition, HAVN Life will also have a
defined route to market.
First Health Canada License received.
Leveraging a highly experienced and proven
Development of formulations that allow management team with a track record of
veterans and frontline workers to optimize building NHP brands.
their mental health.
Investor Deck 2021 4
O U R STO RY
HAVN Life is a part of a global community Through end to end research, extraction,
taking an active part in supporting formulation and delivery, we aspire to
research for microdosing therapies in define and standardize the future of
treating mental health disorders utilizing
modern medicine. With an extensive
psychedelics. Working with Veterans and
team of industry leaders with 20+ years
thought leaders in the military, HAVN
Life is developing innovative clinical trial of experience in this space, HAVN Life
formulations to aid in the recovery of PTSD is formulating the next generation of
and other trauma related disorders. medicine using psychoactive compounds.
Investor Deck 2021 5C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S
Creating positive patient experience and mental health outcomes
Vic Neufeld Tim Moore Gary Leong
Executive Chairman Chief Executive Officer Chief Scientific Officer
• CEO of Aphria for 5 years during large scale • Former CEO of Green Growth Brands, from • Gary was the Chief Scientific Officer at
build up to one of the leading cannabis IPO through to Jan 2019, coming off of the Aphria Inc. in Leamington, ON from its
producers in the world. CEO role leading the Company to ~$1 Billion inception in 2014 to 2019. At Aphria, Gary
• CEO of Jamieson Laboratories for 21 market cap. established and oversaw the Quality
years, Canada’s largest manufacturer and • Former President of Clorox Canada and Assurance, Quality Control, Regulatory
distributor of natural vitamins, minerals, former COO of Synnex Canada. Affairs and Research and Development
concentrated food supplements where he • Managing Director at Brita North America functions.
increased its market share from 7% to 27%. group, responsible for building a new • Gary served as the Chief Scientific Officer
• 15 years’ experience as a CPA and Partner business organization across B2B and B2C Jamieson Laboratories in Windsor, ON for
with Ernst & Young. divisions with both branded and private fourteen (14) years.
label portfolio.
Investor Deck 2021 6C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S
Dr. Ivan Casselman Alexzander Samuelsson Eli Dusenbury Juliana Mollica
Chief Psychedelic Officer Chief Research Officer Chief Financial Officer Director of Innovation and
• Extensive nutraceutical formulation • Lead chemist of a publicly traded extraction • Mr. Dusenbury has served as consultant
Quality Assurance
experience, with several products available company, Alexzander developed intellectual for audit and public practice firms in both • Led projects as the quality assurance
in legal cannabis markets in North America. property and patented methods in the Canada and the US and has held CFO and compliance manager for cannabis
• Research spanning human use of extraction of cannabis oils. positions for the following publicly traded and pharmaceutical companies to ensure
psychedelics (ethnobotany and • Holds a Bachelor of Science majoring in companies: Integral Technologies, Inc. maintenance of GMP requirements,
ethnopharmacy) to the study of plant chemistry at Ryerson University. (resigned June 2018), YDX Innovation Corp. developing QMS for multi-site projects,
science (genetics and analytical chemistry). • Supported start-ups in their strategy (resigned May 2019), Isodiol International compliance training programs, and
• Previous work includes executive level and implementation of capital projects Inc. (since August 2018) and Chemesis (since increasing compliance and quality rates.
cannabis advisory. in Canada, Europe, Central and South September 2018). • Expertise in applications for Drug
• Formerly on the management team of Asia through his consulting company • Obtained his Chartered Professional Establishment Licence and Site Licenses.
NextLeaf during IPO Process. Development Catalyst. Accountant designation in 2011 and holds • Successfully obtained more than 100 NPN
a BBA in business and accounting from product licences in a year.
Capilano University.
Investor Deck 2021 7C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S
Rick Brar Tim Laidler Barinder Rasode
Vice Chairman Director President
• Mr.Brar is the CEO & Chairman of Brains • Tim completed a Master of Counselling at • Served two terms as elected Councilor for
Bioceutical Corp. A global manufacturer and UBC, during which time he spent thousands the City of Surrey.
distributor of Cannabinoid API. of volunteer hours helping create the • Served on the Board of BC’s largest health
• Co-Founder and Former CEO of Zenabis Veterans Transition Network, a non-profit authority, Fraser Health, where she was
Global Inc. one of the leading Canadian organization helping Canadian Veterans responsible for a budget over $3 Billion.
LPs with operations in both medical and nationwide. • Co-found ed Grow Tech Labs, providing
recreation cannabis. • Tim is the Executive Director of the Institute cannabis regulatory expertise with a focus
for Veterans Education and Transition at on post-regulated space.
UBC. The institute focuses on supporting • Founded The National Institute of Cannabis
the needs of veterans in the community as Health and Education (NICHE).
well as supporting cutting edge research
with Veterans.
Investor Deck 2021 8C O L L A B O R AT I O N AC R O S S D I S C I P L I N E S
Sheila Copps Allan Oberman David Mokler
Advisor Advisor Advisor
• The Honourable Sheila Copps was the first • Mr. Oberman served as CEO for Concordia • Dr. David Mokler neuropharmacology,
woman to ever hold the position of Deputy Internationl, a international speciality psychopharmacology, substance abuse,
Prime Minister and served for ten years in pharmeceutical company with sales in 90 drug abuse, brain development, dopamine
the federal cabinet. countries and over 200 medicines. and serotonin including work relevant to the
• Her work on diversity and inclusion, the • Previously served as the CEO of Sagent 5HT2a receptors in psychedelics.
environment and young people has left an Pharmaceuticals Inc., as well as various • Published on the serotonergic system in
indelible mark on Canadian public policy. leadership positions over 14 years including the brain, including papers on LSD, MDMA
She is the author of two books Nobody’s CEO with Teva Pharmaceuticals, Canadas and psychedelics dating back to 1970. He
Baby and Worth Fighting For. second largest generic pharmeceutical has published in the areas of; Dr. Mokler is
company. interested in discovering novel compounds.
• Currently, Mr. Oberman is on the Board of
Directors of Dr. Reddy’s Laboratories, one
of Indias Largest global pharmaceutical
enterprises.
Investor Deck 2021 9PAT H T O M A R K E T
UNREGULATED ROUTE REGULATED ROUTE
TO MARKET TO MARKET
Natural Health Psychedelic
Products Extraction and
Supply
Direct to Contract Supply Academic Formulate Microdosing
Consumers Manufacturer Research Therapies
(White Label) (Dealers License) (Pre-Clinical Trials)
Investor Deck 2021 10State-of-the-art
A lab devoted to the Facility
advancement and Mycology
formulation of regulated Laboratory
and novel psychoactive
compounds. Formulation
Capabilities
Investor Deck 2021 11STATE-OF-THE-ART FACILITY
HAVN Labs operates from a state-of-the-art research facility
located in the South Campus at The University of
British Columbia.
MYCOLOGY LABORATORY
With the ability to expand into a pilot plant in the same facility.
Able to formulate and manufacture in one location.
FORMULATION CAPABILITIES
HAVN Life has secured a Health Canada research license,
which allows for the research and development of psychedelic
compounds. The license allows the Company to conduct this
research prior to securing Licensed Dealer status.
The Licensed Dealer status will be secured by 2021 and will
permit the supply and sale of regulated compounds.
Investor Deck 2021 12HAVN Labs will work with veterans and PTSD groups
across North America to develop strategic evidence
based treatment protocols and optimize formulations to
study mental well being.
Currently global access to research informed
formulations is limited. Those who are studying
psychedelics in research studies and academia rely on
products that are developed ad hoc for each project.
HAVN Labs will provide the standardized psychedelic
compound formulations for academic institutions with
isolates and extractions from our facility that will be
utilized for clinical trials and as APIs for product.
Investor Deck 2021 13ROA D M A P
Finalize Pre-Clinical Manufacture & Distribute Expansion of Distribution
Protocols for at Scale Channels R E TA I L
Compound Extraction Licensed Dealer
and Supply Approval
2020 2021 2022+
Supply Clinical Trials with
Formulate
Received first GMP Certified Natural Publish Analytical LABS
Psychedelic
Health Canada License Compounds Method Results
Therapies for
Clinical Trials
Investor Deck 2021 14C O M PA R A B L E S
Attractive Valuation Relative to Peer Group
Drug Development &
Microdosing/Consumer Brand &
Operational Focus Clinical Research Clinical Wellness Clinics Research & Clinics
Clinical Research
Market Segment Health & Wellness Medicinal Research Health & Wellness Medicinal
Public or Private Public Public Public Public Public
Market Capitalization C$84M C$2.4B C$737M C$174M C$88M
Source: Company Filings - Jan 2021
Investor Deck 2021 15G ROWING M USHROOM MARKET
Global Revenue in 2016 - 2024
40B
35B The global functional food market is
expected to reach $34.3 Billion USD by
$34.292
30B
Billions $USD
2024, registering a CAGR of 8.04% during
$31.717
25B
$29.346
the forecast period (2019-2024).
$27.161
$25.147
20B
$23.290
The market studied is expected to
$21.578
15B
$19.998
$18.540
experience huge demand for Reishi and
10B
Cordyceps and this is why HAVN Life has
5B decided to pursue formulations with these
mushrooms.
2016 2017 2018 2019 2020 2021 2022 2023 2024
Source: Research & Markets - April 2020
Investor Deck 2021 16C A P I TA L I Z AT I O N
Shares
Total Issued & Outstanding 66,971,000
Warrants & Options 21,715,000
Fully Diluted 88,686,000
Notes
• 15.5m Management Escrow over 36 Months
• 16,474,000 shares via pre-IPO financing at CDN $0.25
restricted until January 10, 2021
• In addition to Issued & Oustanding, 14.5m Performance
Warrants remain unearned
Investor Deck 2021 17DISCLAIMER
This presentation is confidential and is being issued by HAVN Life (the “Company”) for informational purposes only. Reliance on frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,”
this presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of “possible,” “projects,” “plans,” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” or
the property or other assets invested. This presentation may not be copied, reproduced, distributed, discussed or used without the “should” occur or be achieved or their negatives or other comparable words. Any forward-looking statements made herein or
express written consent of the Company or its advisors on its behalf, or for any other purpose than the evaluation by the recipient made elsewhere by the Company are made solely based on information available to the Company as of the date hereof and based
of a possible investment in the Company. only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, anticipated events
and trends, the economy and other future conditions. As such, they are subject to inherent uncertainties, risks, assumptions and
The Company does not make any representation or warranty as to the accuracy or completeness of the information in this changes in circumstances that are difficult to predict (including but not limited to risks applicable to early stage ventures and
presentation, and the information herein may not be relied upon by you in evaluating the merits of investing in any securities cannabis organizations), and in many cases outside of the Company’s control, and you should not rely on such forward-looking
referred to herein. This presentation does not contain, nor does it purport to contain, a summary of all of the material information statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited
concerning the Company or the terms and conditions of any potential investment in the Company. If and when you determine to to, any statements about historical results that suggest trends for the Company’s business, any statements of plans, strategies
proceed with discussions and investigations regarding a possible investment in the Company, prospective investors are urged to and objectives of management and any statements of expectation or belief regarding future events. “Future-oriented financial
carry out independent investigations in order to determine their interest in investing in the Company. information” is forward-looking information about prospective results of operations, financial position or cash flows, based on
assumptions about future economic conditions and courses of action, and presented in the format of a historical statement of
In furnishing this presentation to the recipient, the Company and its advisors reserve the right to provide the same or similar financial position, statement of comprehensive income or statement of cash flows. Similarly, a “financial outlook” is forward-
information to other persons and to enter into agreements with other parties regarding the opportunity described in this presentation looking information about prospective financial performance, financial position or cash flows that is based on assumptions about
and to cease to provide the recipient with information on the opportunity, all without notice to the recipient. future economic conditions and courses of action that is not presented in the format of a historical statement of financial position,
statement of comprehensive income or statement of cash flows. Future-oriented financial information and financial outlook made
This presentation is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of herein or made elsewhere by the Company are made solely based on the information available to the Company as of the date
securities in the United States, Canada or any other jurisdiction. No securities commission or similar authority of the United States, hereof and are subject to the same assumptions, risk factors and other qualifications as all other forward-looking information, and
Canada, or any other jurisdiction has reviewed or in any way passed upon this document or the merits of the securities described presented solely for the purpose of conveying the current anticipated expectations of the Company and may not be appropriate
herein, and any representation to the contrary is an offence. for any other purposes.
This presentation does not contain all of the information that would normally appear in a prospectus under applicable Canadian Forward-looking statements and forward-looking information address future events and conditions and therefore involve inherent
or United States securities laws. Neither the delivery of this presentation, at any time, nor any sale made pursuant hereto, will known and unknown risks and uncertainties. Actual results may differ materially from those in the forward looking statements and
imply that the information contained herein is correct as of any time subsequent to the date set forth on the cover page hereof forward-looking information due to risks facing the Company or due to actual facts differing from the assumptions underlying its
or the date at which such information is expressed to be stated, as applicable, and, except as may be required by applicable law, predictions.
the Company is under no obligation to update any of the information contained herein (including forward looking statements and
forward looking information) or to inform the recipient of any matters of which it becomes aware that may affect any matter referred Certain of the information contained in this presentation concerning the industry and its trends and performance is based upon
to in this presentation (including, but not limited to, any error or omission which may become apparent after this presentation has or derived from information provided by third-party consultants, other industry sources and our research. The Company believes
been prepared). such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot
guarantee the accuracy of such information and has not independently verified the assumptions upon which any projections are
This presentation is not intended as an offer or solicitation with respect to the purchase or sale of any financial instrument. If a based.
private placement of the equity securities of the Company occurs, such transaction may not be registered under the Securities Act
of 1933, as amended (the “Act”), or the securities laws of any other jurisdiction, and would be conducted in reliance on exemptions In the event this presentation is considered to be an offering memorandum, a summary of a purchaser’s rights of action and
from the registration requirements of the Act and other applicable laws and subject to selling and transfer restrictions. rescission are included in the Appendix hereto.
Investing in the Company involves significant risks given the early stage nature of the Company’s business. Prior to investing in the
Company, prospective investors are urged to consult with their legal, investment, accounting, tax and other advisors to determine
the risks and consequences of an investment in the Company. Prospective investors should not construe the contents of this
presentation as investment or legal advice.
This presentation contains certain forward-looking statements and forward-looking information. Forward-looking statements are
Investor Deck 2021 18THANK YOU
IR@HAVN LIFE.COM
CSE: HAVN | FRA: 5NP
Investor Deck 19You can also read
